#1 Clinical Trials Search in Europe

Febuxostat

Febuxostat is a medication being studied in clinical trials for the treatment of gout, a form of arthritis caused by high uric acid levels. These trials aim to assess febuxostat’s effectiveness in lowering serum urate levels, its long-term safety profile, and its potential benefits compared to existing treatments like allopurinol. The studies also explore febuxostat’s effects on related conditions like hypertension and coronary artery disease.

Table of Contents

What is Febuxostat?

Febuxostat is a medication primarily used to treat gout and high levels of uric acid in the blood (hyperuricemia). It’s known by several names, including TMX-67, Tei-6720, and Uloric[1]. This drug belongs to a class of medications called xanthine oxidase inhibitors, which work by reducing the production of uric acid in the body[2].

How Febuxostat Works

Febuxostat works by blocking an enzyme called xanthine oxidase. This enzyme is responsible for converting certain substances in the body into uric acid. By inhibiting this enzyme, febuxostat helps to lower the levels of uric acid in the blood[3]. This is important because high levels of uric acid can lead to the formation of crystals in joints and other tissues, causing pain and inflammation associated with gout.

Conditions Treated by Febuxostat

Febuxostat is primarily used to treat the following conditions:

  • Gout: This is a form of arthritis caused by the buildup of uric acid crystals in joints, leading to sudden, severe attacks of pain, redness, and tenderness[1].
  • Hyperuricemia: This condition is characterized by high levels of uric acid in the blood, which can lead to gout if left untreated[2].

Some research is also exploring the potential benefits of febuxostat for other conditions, such as:

  • Coronary Artery Disease: One study investigated whether febuxostat could improve blood flow in the coronary arteries of patients with stable angina (chest pain)[4].
  • Hypertension (High Blood Pressure): Some research has looked into whether febuxostat might have blood pressure-lowering effects[5].

Dosage and Administration

Febuxostat is typically taken orally (by mouth) once daily. The dosage can vary depending on the individual patient and their condition. Common dosages include:

  • 40 mg once daily
  • 80 mg once daily
  • 120 mg once daily (in some cases)[3]

It’s important to note that your doctor will determine the right dosage for you based on your specific situation and how well you respond to the medication. Never adjust your dosage without consulting your healthcare provider first.

Effectiveness of Febuxostat

Several clinical trials have demonstrated the effectiveness of febuxostat in lowering uric acid levels and managing gout symptoms. Some key findings include:

  • A significant percentage of patients achieved serum urate levels below 6.0 mg/dL (the target level for gout management) after taking febuxostat[6].
  • Febuxostat was found to be effective in patients with mild to moderate kidney impairment, which is common in gout patients[7].
  • Long-term studies showed that febuxostat could maintain lower uric acid levels for extended periods, potentially reducing the frequency of gout attacks[8].

Potential Side Effects

Like all medications, febuxostat can cause side effects. Common side effects may include:

  • Liver function abnormalities
  • Nausea
  • Joint pain
  • Rash[3]

It’s important to note that when starting febuxostat, some patients may experience an increase in gout flares initially. This is because rapid changes in uric acid levels can trigger flares. Your doctor may prescribe additional medications to help prevent these flares during the first few months of treatment[3].

Ongoing Research

Researchers continue to study febuxostat to understand its full potential and long-term effects. Some areas of ongoing research include:

  • The effects of febuxostat on joint damage in early gout[9].
  • The potential cardiovascular effects of febuxostat compared to other gout medications[4].
  • The possibility of using lower doses of febuxostat for long-term maintenance in well-controlled gout patients[10].

These ongoing studies may provide more insights into the optimal use of febuxostat and potentially expand its applications in the future.

Aspect Details
Primary Objective To evaluate the efficacy and safety of febuxostat in lowering serum urate levels in patients with gout
Key Comparisons Febuxostat vs. allopurinol and placebo in reducing serum urate levels and preventing gout flares
Dosage Range Typically 40 mg, 80 mg, or 120 mg once daily, with some trials exploring 20 mg and 240 mg doses
Duration of Studies Ranging from 4 weeks to 5 years or more, with some long-term safety studies extending beyond 5 years
Primary Outcomes Percentage of patients achieving serum urate levels <6.0 mg/dL; changes in serum urate levels from baseline
Secondary Outcomes Reduction in gout flares, changes in tophus size, quality of life measures, cardiovascular effects
Special Populations Patients with renal impairment, hypertension, coronary artery disease
Additional Investigations Effects on blood pressure, coronary artery endothelial function, potential for dose tapering in well-controlled patients

FAQ

  • What is the main purpose of febuxostat in gout treatment? The main purpose of febuxostat in gout treatment is to lower serum urate levels in patients with gout. It works by inhibiting xanthine oxidase, an enzyme involved in uric acid production. The goal is to reduce serum urate to levels below 6.0 mg/dL, which can help prevent gout attacks and reduce the formation of urate crystals in joints.
  • How does febuxostat compare to allopurinol in clinical trials? Clinical trials have compared febuxostat to allopurinol, the current standard treatment for gout. These studies assess the efficacy of both drugs in lowering serum urate levels, their safety profiles, and their effects on gout symptoms. Some trials have shown febuxostat to be more effective than allopurinol in reducing serum urate levels, particularly in patients with renal impairment.
  • What are the potential side effects of febuxostat? While specific side effects are not detailed in the provided trial information, clinical studies typically monitor for adverse events. Common side effects of febuxostat may include liver function abnormalities, nausea, and joint pain. Long-term safety studies are conducted to assess the medication's safety profile over extended periods of use.
  • Can febuxostat be used in patients with kidney problems? Yes, febuxostat can be used in patients with kidney problems. Some clinical trials have specifically included patients with mild to moderate renal impairment. Febuxostat may be particularly beneficial for these patients, as it doesn't require dose adjustment in mild to moderate renal impairment, unlike allopurinol.
  • Are there any studies looking at febuxostat's effects beyond gout treatment? Yes, some clinical trials are exploring febuxostat's potential effects beyond gout treatment. For example, studies have investigated its impact on blood pressure in hypertensive patients and its influence on coronary artery endothelial function in patients with coronary artery disease. These studies aim to understand the broader cardiovascular effects of lowering uric acid levels with febuxostat.

Ongoing Clinical Trials on Febuxostat

  • Study of osimertinib and febuxostat to improve drug delivery in patients with EGFR-mutated non-small cell lung cancer without brain metastases

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Stopping Allopurinol or Febuxostat in Gout Patients in Remission

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Gout: Comparing Immediate vs. Delayed Use of Febuxostat for Patients with Acute Gout Attacks

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Febuxostat: A non-purine selective xanthine oxidase inhibitor used to treat chronic gout and hyperuricemia. It works by reducing the production of uric acid in the body.
  • Gout: A form of arthritis caused by the buildup of uric acid crystals in joints, leading to inflammation, pain, and swelling.
  • Serum urate: The level of uric acid in the blood. High levels can lead to gout and are typically the target of gout treatments.
  • Hyperuricemia: A condition characterized by abnormally high levels of uric acid in the blood, typically defined as serum urate levels above 6.8 mg/dL.
  • Allopurinol: A commonly used medication for gout that also works by inhibiting xanthine oxidase to reduce uric acid production.
  • Tophus (plural: tophi): A deposit of uric acid crystals in the soft tissues, often found in people with long-standing gout.
  • Xanthine oxidase: An enzyme involved in the production of uric acid in the body, which is the target of medications like febuxostat and allopurinol.
  • Renal impairment: Reduced kidney function, which can affect the body's ability to excrete uric acid and may complicate gout treatment.
  • Uricosuric drugs: Medications that increase the excretion of uric acid in urine, used as an alternative treatment for gout.
  • Ambulatory Blood Pressure Monitor (ABPM): A device used to measure blood pressure at regular intervals over a 24-hour period, providing a more comprehensive view of a person's blood pressure.

References

  1. https://clinicaltrials.gov/study/NCT00174941
  2. https://clinicaltrials.gov/study/NCT00174967
  3. https://clinicaltrials.gov/study/NCT00174915
  4. https://clinicaltrials.gov/study/NCT01763996
  5. https://clinicaltrials.gov/study/NCT01701622
  6. https://clinicaltrials.gov/study/NCT00102440
  7. https://clinicaltrials.gov/study/NCT00430248
  8. https://clinicaltrials.gov/study/NCT00175019
  9. https://clinicaltrials.gov/study/NCT01078389
  10. https://clinicaltrials.gov/study/NCT06622603